16th National Conference of the Primary Care Diabetes Society | Diabetes on the Net

Diabetes on the Net is intended for healthcare professionals

16th National
Conference of the Primary Care Diabetes Society

We are delighted to invite you to virtually attend this year’s National Conference of the Primary Care Diabetes Society (PCDS), our annual, free-to-attend, two-day virtual conference taking place on 5–6 November 2020. The title of this year’s conference is ‘Diabetes in a new world: Crisis, challenge and opportunity’, which reflects not just the evolving situation with COVID-19 but also broader underlying changes in the world of diabetes.

While the format is changing this year, you will, as ever, be able to benefit from clinically focused education on a range of topics that are most relevant to the practicalities of managing diabetes in primary care today. To name just a few of these, we have experts presenting on mental health, prescribing fundamentals, insulin management, the diabetic foot, and the all-important new ways-of-working.

We very much hope that you can join us for this key event in the 2020 diabetes calendar.

Why attend? This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more

Ask the experts your burning questions through the LIVE Q&A at the end of each session

Log on anytime during the two days from the comfort of your own home to view the sessions

Don’t worry if you miss something, all of the content will be available on-demand

Claim 11 CPD points for the full two-day virtual conference

Register now to the 2-day event

5-6 November 2020

Days
Hours
Minutes
Seconds

Agenda for the
16th National Conference 2020

09.15 – 09.25

Session 1

Chair’s introduction

Clare Hambling

09.25 – 09.55

The National picture

Jonathan Valabhji

15 minute break

10.10 – 10.40

ORAL SEMAGLUTIDE (RYBELSUS®▼) in clinical practice

Matt Capehorn & Waqas Tahir

15 minute break

10.55 – 11.25

What has COVID-19 taught us?

Kamlesh Khunti

15 minute break

11.40 – 12.20

Session 2

‘In Practice’ masterclasses

Rotation 1

1. New ways of working post-COVID-19 – performing remote reviews

Jane Diggle

2. Prescribing fundamentals

Sarah Davies & Sanjay Tanna

3. Insulin

Su Down

15 minute break

12.35 – 13.05

CREDENCE: A paradigm shift in the management of Diabetic Kidney Disease (DKD)

James Burton & Amrit Lamba

15 minute break

13.20 – 14.00

Rotation 2

1. New ways of working post-COVID-19 – performing remote reviews

Jane Diggle

2. Prescribing fundamentals

Sarah Davies & Sanjay Tanna

3. Insulin

Su Down

15 minute break

14.15 – 14.45

Session 3

Mental health

Mark Davies

15 minute break

15.00 – 15.30

Managing Cardiovascular risk in Type 2 Diabetes: Evidence into Primary Care Practice

Naresh Kanumilli

15 minute break

15.45 – 16.15

The opportunity that lies in every crisis

Stephen Lawrence

16.15 – 16.25

Chair’s concluding remarks

Clare Hambling

09.00 – 09.10

Session 4

Chair’s introduction

Clare Hambling

09.10 – 09.40

Heart failure

Yassir Javaid

15 minute break

09.55 – 10.25

Sponsored symposium

09.55 – 10.25

The multiple effects of SGLT2 inhibitors on the Cardio–Renal–Metabolic system in type 2 diabetes

Ameet Bakhai & Partha Kar

15 minute break

10.40 – 11.10

Updates in lifestyle

Jason Gill

15 minute break

11.25 – 12.05

Session 5

‘In Practice’ masterclasses

Rotation 1

1. Diabetic foot disease

Vanessa Goulding

2. ‘Funny numbers’: Interpreting results

Clare Hambling & Patrick Wainwright

3. Vulnerable groups in diabetes

Lisa Devine & Margaret Griffin

4. FreeStyle Libre and Time In Range

Emma Wilmot

15 minute break

12.20 – 13.00

Rotation 2

1. Diabetic foot disease

Vanessa Goulding

2. ‘Funny numbers’: Interpreting results

Clare Hambling & Patrick Wainwright

3. Vulnerable groups in diabetes

Lisa Devine & Margaret Griffin

15 minute break

13.15 – 13.45

Session 6

Dietary advice in diabetes

Pam Dyson

15 minute break

14.00 – 14.30

Preventing Cardiovascular Events in Type 2 Diabetes

Yassir Javaid

15 minute break

14.45 – 15.15

Diabetes Distilled

Kevin Fernando

15.15 – 15.25

Chair’s concluding remarks

Clare Hambling

09.15 – 09.25

Session 1

Chair’s introduction

Clare Hambling

09.25 – 09.55

The National picture

Jonathan Valabhji

15 minute break

10.10 – 10.40

ORAL SEMAGLUTIDE (RYBELSUS®▼) in clinical practice

Matt Capehorn & Waqas Tahir

15 minute break

10.55 – 11.25

What has COVID-19 taught us?

Kamlesh Khunti

15 minute break

11.40 – 12.20

Session 2

‘In Practice’ masterclasses

Rotation 1

1. New ways of working post-COVID-19 – performing remote reviews

Jane Diggle

2. Prescribing fundamentals

Sarah Davies & Sanjay Tanna

3. Insulin

Su Down

15 minute break

12.35 – 13.05

CREDENCE: A paradigm shift in the management of Diabetic Kidney Disease (DKD)

James Burton & Amrit Lamba

15 minute break

13.20 – 14.00

Rotation 2

1. New ways of working post-COVID-19 – performing remote reviews

Jane Diggle

2. Prescribing fundamentals

Sarah Davies & Sanjay Tanna

3. Insulin

Su Down

15 minute break

14.15 – 14.45

Session 3

Mental health

Mark Davies

15 minute break

15.00 – 15.30

Managing Cardiovascular risk in Type 2 Diabetes: Evidence into Primary Care Practice

Naresh Kanumilli

15 minute break

15.45 – 16.15

The opportunity that lies in every crisis

Stephen Lawrence

16.15 – 16.25

Chair’s concluding remarks

Clare Hambling

09.00 – 09.10

Session 4

Chair’s introduction

Clare Hambling

09.10 – 09.40

Heart failure

Yassir Javaid

15 minute break

09.55 – 10.25

Sponsored symposium

09.55 – 10.25

The multiple effects of SGLT2 inhibitors on the Cardio–Renal–Metabolic system in type 2 diabetes

Ameet Bakhai & Partha Kar

15 minute break

10.40 – 11.10

Updates in lifestyle

Jason Gill

15 minute break

11.25 – 12.05

Session 5

‘In Practice’ masterclasses

Rotation 1

1. Diabetic foot disease

Vanessa Goulding

2. ‘Funny numbers’: Interpreting results

Clare Hambling & Patrick Wainwright

3. Vulnerable groups in diabetes

Lisa Devine & Margaret Griffin

4. FreeStyle Libre and Time In Range

Emma Wilmot

15 minute break

12.20 – 13.00

Rotation 2

1. Diabetic foot disease

Vanessa Goulding

2. ‘Funny numbers’: Interpreting results

Clare Hambling & Patrick Wainwright

3. Vulnerable groups in diabetes

Lisa Devine & Margaret Griffin

15 minute break

13.15 – 13.45

Session 6

Dietary advice in diabetes

Pam Dyson

15 minute break

14.00 – 14.30

Preventing Cardiovascular Events in Type 2 Diabetes

Yassir Javaid

15 minute break

14.45 – 15.15

Diabetes Distilled

Kevin Fernando

15.15 – 15.25

Chair’s concluding remarks

Clare Hambling

A 2-Day Virtual Conference
Including a LIVE Q&A After Every Session

Conference
Speakers

Mark Davies

Consultant Clinical Psychologist, Belfast Health and Social Care Trust

Sarah Davies

GPwSI in Diabetes, Cardiff

Lisa Devine

GP, Co. Wicklow

Jane Diggle

Specialist Practitioner Practice Nurse, South Kirkby

Su Down

Diabetes Nurse Consultant, Somerset

Pam Dyson

Research Dietitian, Oxford

Kevin Fernando

GPwSI Diabetes & Medical Education, North Berwick

Jason Gill

Professor of Cardiometabolic Health, Institute of Cardiovascular and Medical Sciences, University of Glasgow

Vanessa Goulding

Highly Specialist Podiatrist, Cardiff Royal Infirmary

Margaret Griffin

Consultant Endocrinologist, Dublin

Clare Hambling

GP, Norfolk, and Chair of the PCDS

Yassir Javaid

GPwSI Cardiology & Cardiovascular Lead, Nene CCG, Northampton

Kamlesh Khunti

Professor of Primary Care Diabetes and Vascular Medicine, Leicester

Stephen Lawrence

GPSI, Kent and Associate Clinical Professor, Warwick University Medical School

Sanjay Tanna

Lead Clinical Pharmacist, Blackpool

Jonathan Valabhji

National Clinical Director for Diabetes and Obesity, NHS England & NHS Improvement, London

Patrick Wainwright

Consultant in Chemical Pathology and Metabolic Medicine
Emma-Wilmot

Emma Wilmot

Consultant Diabetologist, University Hospitals of Derby & Burton Honorary Assistant Professor, University of Nottingham Founder, ABCD Diabetes Technology Network UK

Conference
Sponsors

GOLD SPONSOR

Napp Pharmaceuticals Limited

Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. We strive to offer new medicines and initiatives that support the NHS in delivering effective, high-quality, sustainable healthcare for the benefit of patients

SILVER SPONSORS

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit www.astrazeneca.co.uk

Boehringer Ingelheim and Lilly Diabetes Alliance

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centres on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need

Eli Lilly and Company Ltd

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.co.uk

Novo Nordisk

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.

For more information visit www.novonordisk.co.uk

Masterclass sponsor

Abbott’s Diabetes Care Division

Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk

BRONZE SPONSORS

AgaMatrix

AgaMatrix manufactures and supplies WaveSense JAZZ™ blood glucose meters, diabetes data management solutions and provides services and support to help you reduce the cost of diabetes care.

With uncompromising accuracy as our cornerstone, we strive to ensure the highest quality diabetes monitoring products and services are supplied at the lowest possible cost.

Find out about our innovative new device, JAZZ™ DoseCoach, the UK’s first evidence-based basal insulin only advisor with built-in blood glucose meter.  The device helps patients with type 2 diabetes optimise their once daily insulin glargine dose and is proven to reduce HbA1c.

BD

BD Diabetes Care have been specialising in the design and manufacture of insulin needles and syringes for over 90 years. BD’s culture of innovation and continuous improvement has enhanced the patient experience to enable better diabetes therapy and outcomes. BD and Me™ and BD Injection technique training programmes for HCPs and patients, have been designed to provide information on correct injection technique to better manage diabetes for those injecting1.

>1.Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013 Oct;39(5):445-53. doi: 10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22.

Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.

In the UK, where some of medicines have been helping patients for more than 50 years, we have a portfolio of over 500 products that include branded, generic, over the counter, antiretroviral and biosimilar medicines. Learn more at www.mylan.co.uk.

OTHER SPONSORS

Mundipharma Pharmaceuticals Ltd.

Mundipharma Pharmaceuticals Ltd. has been at the forefront of providing healthcare solutions to the Irish market since 1973. We work at a local level but have all the resources and experience of a global network of independent associated pharmaceutical companies. MPL are actively involved in the development and supply of innovative products, and our focus is directed at improving the quality of life of those suffering from chronic debilitating diseases. Our primary areas of expertise are the areas of diabetes (Invokana® & Vokanamet®), respiratory (flutiform®, flutiform K-haler®), and biosimilars (Pelmeg®, Herzuma® & Truxima®). We look to partnering the medical profession and the patient to manage these conditions over the long term and to seek new and ever better solutions.

Benecol

Making simple switches to your diet can make a big difference. Benecol offer a range of tasty foods with added plant stanols, including yogurt drinks and spreads. The efficacy of plant stanols in Benecol® foods has been proven in over 80 clinical studies, simply having 2g of plant stanols, daily with meals, can lower your cholesterol by 10% on average in just 2-3 weeks*. For more information on how Benecol products with plant stanols work alone or in combination with cholesterol lowering medication come and see us at our stand.

*Plant stanol ester has been shown to lower cholesterol. High cholesterol is a risk factor in the development of coronary heart disease. A daily intake of 1.5–2.4g plant stanols lower cholesterol by 7–10% in 2–3 weeks.

Sanofi

Sanofi is moving beyond conventional thinking in diabetes management. Our advanced treatments and diagnostic tools and support services are just the beginning. Sanofi diabetes are proud to support the PCDS meetings to continue working hard with those who are dedicated to developing diabetes care. Our goal is to develop innovative solutions to help people with diabetes live as people not as patients.

Servier Laboratories

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests in average 25% of its turnover (excluding generics) every year in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.